Laboratory of Molecular Parasitology, Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA.
Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
Trends Parasitol. 2018 Jan;34(1):64-79. doi: 10.1016/j.pt.2017.08.011. Epub 2017 Sep 22.
Human onchocerciasis - commonly known as river blindness - is one of the most devastating yet neglected tropical diseases, leaving many millions in sub-Saharan Africa blind and/or with chronic disabilities. Attempts to eliminate onchocerciasis, primarily through the mass drug administration of ivermectin, remains challenging and has been heightened by the recent news that drug-resistant parasites are developing in some populations after years of drug treatment. Needed, and needed now, in the fight to eliminate onchocerciasis are new tools, such as preventive and therapeutic vaccines. This review summarizes the progress made to advance the onchocerciasis vaccine from the research laboratory into the clinic.
人体盘尾丝虫病,俗称河盲症,是一种最具破坏性但却被忽视的热带病之一,致使撒哈拉以南非洲地区的数百万人失明和/或患有慢性残疾。人们曾试图通过大规模使用伊维菌素来消除盘尾丝虫病,但一直面临挑战,最近有消息称,在经过多年的药物治疗后,一些人群中的寄生虫已经产生了耐药性,这使得情况更加复杂。在消除盘尾丝虫病的斗争中,我们需要新的工具,如预防性和治疗性疫苗。这篇综述总结了将盘尾丝虫病疫苗从研究实验室推进到临床应用所取得的进展。